GlassScriptPhysician profile
Paul Thomas Provance
NPI 1760429740
$5,969.66
in general payments reported to CMS, 2019-2025
45 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $472 · 2021: $1,069 · 2022: $1,053 · 2023: $1,000 · 2024: $1,022 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $647.31 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $594.97 | 2021-2025 | |
| Lilly USA, LLC | $513.15 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $399.46 | 2021-2025 | |
| Novo Nordisk INC | $374.04 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $352.49 | 2020-2025 | |
| Glaxosmithkline, LLC. | $320.19 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $277.74 | 2020-2025 | Nexletol |
| Abbott Laboratories | $259.94 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.47 | 2023-2025 | Xifaxan |
| Amgen INC. | $215.95 | 2020-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.15 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $133.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.72 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $126.59 | 2021-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.12 | 2023-2025 | Veozah, Myrbetriq |
| Antares Pharma, INC. | $100.73 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.28 | 2021-2024 | Jardiance |
| Inogen, INC. | $89.50 | 2022-2025 | Inogen At Home Stationary Concentrator |
| Takeda Pharmaceuticals U.S.A., INC. | $73.94 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $68.96 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $64.52 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.26 | 2020-2021 | |
| Allergan, INC. | $59.10 | 2020 | |
| Sanofi-Aventis U.S. LLC | $43.05 | 2022-2023 | |
| Lundbeck LLC | $41.89 | 2023-2024 | Vyepti |
| Axsome Therapeutics, INC. | $40.72 | 2025 | Auvelity |
| Dexcom, INC. | $37.01 | 2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $28.62 | 2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $26.19 | 2024 | Voquezna |
| Medtronic, INC. | $23.08 | 2025 | Intellis Adaptivestim |
| Optinose US, INC. | $22.83 | 2024 | |
| Corium, LLC | $19.77 | 2023 | Adlarity |
| Kowa Pharmaceuticals America, INC. | $19.06 | 2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $18.89 | 2020 | |
| Sumitomo Pharma America, INC. | $17.96 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $17.80 | 2021 | |
| Exact Sciences Corporation | $17.59 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $16.22 | 2021 | |
| Corcept Therapeutics | $15.87 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $15.70 | 2022 | |
| Merck Sharp & Dohme LLC | $15.46 | 2023 | Verquvo, Belsomra |
| Horizon Therapeutics Plc | $13.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Provance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.